Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Provided By GlobeNewswire
Last update: Sep 3, 2024
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period
Over 30% of patients achieved seizure freedom status while on relutrigine
Read more at globenewswire.com
